Marie-France Penet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie-France Penet has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Zaver M. Bhujwalla
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland
8 shared publications Zaver M. Bhujwalla
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
5 shared publicationsYelena Mironchik
Johns Hopkins University, School of Medicine, Baltimore, MD
4 shared publicationsBalaji Krishnamachary
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
3 shared publications- Balaji Krishnamachary
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publications Dmitri Artemov
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science The Johns Hopkins University School of Medicine Baltimore MD USA
3 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Single-cell RNA sequencing reveals a distinct resident memory T-cell phenotype in prurigo nodularis
Prurigo nodularis (PN) is a chronic inflammatory skin disease with a poorly understood pathogenesis. We performed single-cell RNA sequencing on skin samples from patients with PN to characterize tissue-resident memory T-cell (TRM) subsets. Our findings reveal heterogeneous populations of PN CD4 TRMs in relation to the transcriptomes of atopic dermatitis and psoriasis, with immunological heterogeneity correlating with treatment response.
- 11 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Open AccessSingle-cell RNA sequencing reveals a distinct resident memory T-cell phenotype in prurigo nodularis
Prurigo nodularis (PN) is a chronic inflammatory skin disease with a poorly understood pathogenesis. We performed single-cell RNA sequencing on skin samples from patients with PN to characterize tissue-resident memory T-cell (TRM) subsets. Our findings reveal heterogeneous populations of PN CD4 TRMs in relation to the transcriptomes of atopic dermatitis and psoriasis, with immunological heterogeneity correlating with treatment response.
- Open Access
Glioblastoma Treatment by Systemic Actinium-225 α-particle Dendrimer-radioconjugates is Improved by Chemotherapy
RATIONALE: The poor prognosis of glioblastoma is largely due to drug resistance and tumor location that, together, make it difficult to treat aggressively without affecting the rest of the brain. METHODOLOGY: High-energy, short-range (40-80µm) dendrimer-delivered α-particles could address both challenges, because (1) they cause complex, highly cytotoxic double-strand DNA breaks, and (2) irradiation of the neighboring brain is minimal, since dendrimers selectively delivers them to tumors. Since cancer cells that are not directly hit by α-particles will likely not be killed, the patterns of tumor irradiation affect efficacy. Systemically injected dendrimers extensively accumulate in glioblastomas, where they are taken up by tumor associated macrophages (TAMs), which tend to infiltrate tumors. We hypothesized that dendrimers labeled with α-particle emitters, when being carried by TAMs, could more evenly irradiate glioblastomas, improving survival. In this study, the efficacy of dendrimers radiolabeled with the α-particle emitter actinium-225 (dendrimer-radioconjugates) was evaluated when administered alone and/or after temozolomide, in a syngeneic immune-competent orthotopic GL261-C57BL/6 mouse model. RESULTS: Systemically-administered dendrimer-radioconjugates, at activities that did not result in long-term toxicities, prolonged survival of mice with orthotopic GL261 tumors, compared to standard-of-care temozolomide (39 vs 31 days mean survival, p=0.0061) and non-treated animals (30 days, p=0.0009). Importantly, injection of temozolomide 24 hours before administration of dendrimer-radioconjugates further improved survival remarkably (44 days). This improvement in efficacy was attributed to: (1) the significant increase (by 33%) in tumor absorbed doses delivered by dendrimer-radioconjugates when injected after chemotherapy, without altering normal organ dosimetry, while sparing the tumor-surrounding healthy brain; (2) the potentially deeper tumor penetration of dendrimer-radioconjugates, suggested by the enhancement of dendrimer penetration within GL261-spheroids, employed as model tumor-avascular regions and/or TAM-free regions; and/or (3) the formation of a more lethal cocktail when both modalities acted on same cancer cells, that was correlated with increased levels of dendrimer-radioconjugates associating with GL261 cells in vitro and with greater incidences of karyomegaly in vivo . CONCLUSIONS: This study demonstrates the potential of a ‘brain tumor targeted’ systemic actinium-225 radiopharmaceutical therapy that inhibits growth of glioblastoma cells and prolongs survival of mice with orthotopic brain tumors, further improved by standard-of-care temozolomide, without notable toxicities.
Open AccessGlioblastoma Treatment by Systemic Actinium-225 α-particle Dendrimer-radioconjugates is Improved by Chemotherapy
RATIONALE: The poor prognosis of glioblastoma is largely due to drug resistance and tumor location that, together, make it difficult to treat aggressively without affecting the rest of the brain. METHODOLOGY: High-energy, short-range (40-80µm) dendrimer-delivered α-particles could address both challenges, because (1) they cause complex, highly cytotoxic double-strand DNA breaks, and (2) irradiation of the neighboring brain is minimal, since dendrimers selectively delivers them to tumors. Since cancer cells that are not directly hit by α-particles will likely not be killed, the patterns of tumor irradiation affect efficacy. Systemically injected dendrimers extensively accumulate in glioblastomas, where they are taken up by tumor associated macrophages (TAMs), which tend to infiltrate tumors. We hypothesized that dendrimers labeled with α-particle emitters, when being carried by TAMs, could more evenly irradiate glioblastomas, improving survival. In this study, the efficacy of dendrimers radiolabeled with the α-particle emitter actinium-225 (dendrimer-radioconjugates) was evaluated when administered alone and/or after temozolomide, in a syngeneic immune-competent orthotopic GL261-C57BL/6 mouse model. RESULTS: Systemically-administered dendrimer-radioconjugates, at activities that did not result in long-term toxicities, prolonged survival of mice with orthotopic GL261 tumors, compared to standard-of-care temozolomide (39 vs 31 days mean survival, p=0.0061) and non-treated animals (30 days, p=0.0009). Importantly, injection of temozolomide 24 hours before administration of dendrimer-radioconjugates further improved survival remarkably (44 days). This improvement in efficacy was attributed to: (1) the significant increase (by 33%) in tumor absorbed doses delivered by dendrimer-radioconjugates when injected after chemotherapy, without altering normal organ dosimetry, while sparing the tumor-surrounding healthy brain; (2) the potentially deeper tumor penetration of dendrimer-radioconjugates, suggested by the enhancement of dendrimer penetration within GL261-spheroids, employed as model tumor-avascular regions and/or TAM-free regions; and/or (3) the formation of a more lethal cocktail when both modalities acted on same cancer cells, that was correlated with increased levels of dendrimer-radioconjugates associating with GL261 cells in vitro and with greater incidences of karyomegaly in vivo . CONCLUSIONS: This study demonstrates the potential of a ‘brain tumor targeted’ systemic actinium-225 radiopharmaceutical therapy that inhibits growth of glioblastoma cells and prolongs survival of mice with orthotopic brain tumors, further improved by standard-of-care temozolomide, without notable toxicities.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6305
Abstract 6305: Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft
Cancer-induced cachexia is commonly observed in pancreatic cancer. The syndrome induces significant weight loss and leads to morbidity, intolerance to chemotherapy, and mortality. While performing metabolic characterization of the brain and plasma of mice with a cachexia-inducing human pancreatic cancer xenograft we identified significant changes in glutamine metabolism [1] that led us to investigate the effects of altering tumor glutamine metabolism on weight loss. We genetically engineered cachexia inducing Pa04C cells to express shRNA downregulating the glutamine transporter SLC1A5. Tumors derived from Pa04C cells with downregulated SLC1A5 (CSh cells and tumors) exhibited significantly delayed tumor growth compared to empty vector (EV) or wild type (WT) tumors, but escaped growth delay approximately 60 days after inoculation, although SLC1A5 mRNA and protein remained significantly downregulated. Despite tumor growth, mouse weight reduction was significantly attenuated at matched EV and CSh tumor volumes. We next sought to investigate if tumors derived from cells isolated from escaped CSh tumor (TSh cells and tumors) continued to exhibit growth delay and attenuated weight loss when re-inoculated in mice. Quantitative transcriptome profiling by RNA-seq was performed to determine differentially expressed genes in CSh and TSh cells compared to EV cells. Method: EV, CSh or TSh cells were inoculated subcutaneously in male mice. Tumor volumes and weights of tumor bearing mice were recorded until tumors were harvested at ~ 500 mm3 for molecular characterization. RNA was isolated in triplicate from EV, CSh and TSh cells. Transcriptomic analysis was performed by RNA sequencing on a NovaSeq 6000 PE150 platform. All bioinformatics analysis was performed with assistance from the NOVOGENE informatics group. Results: Tumors derived from TSh cells did not exhibit any growth delay unlike tumors derived from CSh cells. SLC1A5 expression remained downregulated in TSh cells and tumors. Despite the loss of growth delay, mice with TSh tumors continued to exhibit attenuated weight loss identifying, suggesting the glutamine transporter as a potential treatment strategy to reduce cachexia. Transcriptomic analysis allowed us to identify the adaptive changes that occurred in CSh tumors that allowed these tumors to escape growth delay despite SLC1A5 downregulation. Transcriptomic differences between TSh and CSh cells were primarily in pathways related to amino acid metabolism, inflammation and the extracellular matrix. These transcriptomic differences allow the identification of novel targets that can be used in combination with glutamine transporter downregulation to arrest the growth of pancreatic cancer cells in vivo. Supported by NIH R35 CA209960 and R01 CA193365. 1) J Cachexia Sarcopenia Muscle. 2020 Dec; 11(6): 1487-1500. Citation Format: Balaji Krishnamachary, Ishwarya Sivakumar, Yelena Mironchik, Raj Kumar Sharma, Santosh Kumar Bharti, Marie-France Penet, Paul Winnard, Eibhlin Goggins, Jiefu Jin, Anirban Maitra, Michael G. Goggins, Zaver M. Bhujwalla. Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6305.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6305
Open AccessAbstract 6305: Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft
Cancer-induced cachexia is commonly observed in pancreatic cancer. The syndrome induces significant weight loss and leads to morbidity, intolerance to chemotherapy, and mortality. While performing metabolic characterization of the brain and plasma of mice with a cachexia-inducing human pancreatic cancer xenograft we identified significant changes in glutamine metabolism [1] that led us to investigate the effects of altering tumor glutamine metabolism on weight loss. We genetically engineered cachexia inducing Pa04C cells to express shRNA downregulating the glutamine transporter SLC1A5. Tumors derived from Pa04C cells with downregulated SLC1A5 (CSh cells and tumors) exhibited significantly delayed tumor growth compared to empty vector (EV) or wild type (WT) tumors, but escaped growth delay approximately 60 days after inoculation, although SLC1A5 mRNA and protein remained significantly downregulated. Despite tumor growth, mouse weight reduction was significantly attenuated at matched EV and CSh tumor volumes. We next sought to investigate if tumors derived from cells isolated from escaped CSh tumor (TSh cells and tumors) continued to exhibit growth delay and attenuated weight loss when re-inoculated in mice. Quantitative transcriptome profiling by RNA-seq was performed to determine differentially expressed genes in CSh and TSh cells compared to EV cells. Method: EV, CSh or TSh cells were inoculated subcutaneously in male mice. Tumor volumes and weights of tumor bearing mice were recorded until tumors were harvested at ~ 500 mm3 for molecular characterization. RNA was isolated in triplicate from EV, CSh and TSh cells. Transcriptomic analysis was performed by RNA sequencing on a NovaSeq 6000 PE150 platform. All bioinformatics analysis was performed with assistance from the NOVOGENE informatics group. Results: Tumors derived from TSh cells did not exhibit any growth delay unlike tumors derived from CSh cells. SLC1A5 expression remained downregulated in TSh cells and tumors. Despite the loss of growth delay, mice with TSh tumors continued to exhibit attenuated weight loss identifying, suggesting the glutamine transporter as a potential treatment strategy to reduce cachexia. Transcriptomic analysis allowed us to identify the adaptive changes that occurred in CSh tumors that allowed these tumors to escape growth delay despite SLC1A5 downregulation. Transcriptomic differences between TSh and CSh cells were primarily in pathways related to amino acid metabolism, inflammation and the extracellular matrix. These transcriptomic differences allow the identification of novel targets that can be used in combination with glutamine transporter downregulation to arrest the growth of pancreatic cancer cells in vivo. Supported by NIH R35 CA209960 and R01 CA193365. 1) J Cachexia Sarcopenia Muscle. 2020 Dec; 11(6): 1487-1500. Citation Format: Balaji Krishnamachary, Ishwarya Sivakumar, Yelena Mironchik, Raj Kumar Sharma, Santosh Kumar Bharti, Marie-France Penet, Paul Winnard, Eibhlin Goggins, Jiefu Jin, Anirban Maitra, Michael G. Goggins, Zaver M. Bhujwalla. Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6305.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6353
Abstract 6353: Metabolic changes in the spleen and pancreas induced by PDAC xenografts with or without glutamine transporter downregulation
Introduction: Our ongoing studies are focused on characterizing metabolic changes induced in the organs of mice with cachexia-inducing Pa04C human pancreatic cancer xenografts. Because pancreatic cancer cells are glutamine dependent [1], we downregulated the glutamine transporter SLC1A5 in Pa04C cells to determine if metabolic changes induced in the spleen and pancreas by Pa04C tumors were normalized when SLC1A5 was downregulated in these tumors. Metabolic patterns were characterized using high-resolution quantitative 1H magnetic resonance spectroscopy (MRS) of spleen and pancreas tissue obtained from normal mice and mice with Pa04C tumors and mice with Pa04C tumors with SLC1A5 downregulated. Method: Patient derived cachexia-inducing Pa04C pancreatic cancer cells were lentivirally transduced to express shRNA to stably downregulate SLC1A5. Mice were euthanized once tumors were ~500 mm3, the spleen and pancreas were excised and snap frozen. Snap frozen spleen (normal n= 5, Pa04C n= 11, Pa04C_SLC1A5 n= 10) and pancreas (normal n= 4, Pa04C n= 16, Pa04C_SLC1A5 n= 10) tissue samples were pulverized for dual phase extraction. The aqueous phase was used for 1H MRS analysis. Topspin 3.5 software was used for data processing and analyses. Results and Discussion: Significant downregulation of SLC1A5 mRNA and protein was confirmed in Pa04C_SLC1A5 cells and tumors. SLC1A5 downregulation resulted in significant growth delay and attenuation of weight loss. A comparison of normal mice vs empty vector/wild type tumor (EV/WT) bearing mice identified significant changes in succinate, aspartate and fumarate in the spleen, lactate, acetate, pyruvate, methionine, asparagine, creatine, choline phosphocholine, uracil, histidine and phenylalanine in the pancreas, with leucine, isoleucine, valine, alanine, glutamate, glutamine, glutathione, glycerophosphocholine, glycine, glucose and tyrosine commonly altered in the spleen and pancreas. A comparison of normal vs Pa04C_ SLC1A5 tumor bearing mice identified similar metabolic changes in the spleen and pancreas but these were reduced. Fumarate did not change in the spleen, and of the metabolic changes common to spleen and pancreas, glutamine did not change when tumor SLC1A5 was downregulated. Metabolite changes induced only in the pancreas were also similar to normal vs EV/WT with the exception of a change in glutamine with SLC1A5 downregulation and no change in lactate. Our data highlight the profound metabolic changes in spleen and pancreas metabolism that occur with growth of a cachexia-inducing pancreatic cancer xenograft, and the impact on these metabolic patterns as a result of downregulating the glutamine transporter in these cancer cells. The metabolic patterns identified in the spleen and pancreas may provide novel targets to reduce the morbidity from cachexia. Reference: 1. Son J et al, Nature. 2013;496(7443):101-5. Citation Format: Raj Kumar Sharma, Santosh Kumar Bharti, Balaji Krishnamachary, Yelena Mironchik, Paul Winnard Jr., Marie-France Penet, Zaver M. Bhujwalla. Metabolic changes in the spleen and pancreas induced by PDAC xenografts with or without glutamine transporter downregulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6353.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6353
Open AccessAbstract 6353: Metabolic changes in the spleen and pancreas induced by PDAC xenografts with or without glutamine transporter downregulation
Introduction: Our ongoing studies are focused on characterizing metabolic changes induced in the organs of mice with cachexia-inducing Pa04C human pancreatic cancer xenografts. Because pancreatic cancer cells are glutamine dependent [1], we downregulated the glutamine transporter SLC1A5 in Pa04C cells to determine if metabolic changes induced in the spleen and pancreas by Pa04C tumors were normalized when SLC1A5 was downregulated in these tumors. Metabolic patterns were characterized using high-resolution quantitative 1H magnetic resonance spectroscopy (MRS) of spleen and pancreas tissue obtained from normal mice and mice with Pa04C tumors and mice with Pa04C tumors with SLC1A5 downregulated. Method: Patient derived cachexia-inducing Pa04C pancreatic cancer cells were lentivirally transduced to express shRNA to stably downregulate SLC1A5. Mice were euthanized once tumors were ~500 mm3, the spleen and pancreas were excised and snap frozen. Snap frozen spleen (normal n= 5, Pa04C n= 11, Pa04C_SLC1A5 n= 10) and pancreas (normal n= 4, Pa04C n= 16, Pa04C_SLC1A5 n= 10) tissue samples were pulverized for dual phase extraction. The aqueous phase was used for 1H MRS analysis. Topspin 3.5 software was used for data processing and analyses. Results and Discussion: Significant downregulation of SLC1A5 mRNA and protein was confirmed in Pa04C_SLC1A5 cells and tumors. SLC1A5 downregulation resulted in significant growth delay and attenuation of weight loss. A comparison of normal mice vs empty vector/wild type tumor (EV/WT) bearing mice identified significant changes in succinate, aspartate and fumarate in the spleen, lactate, acetate, pyruvate, methionine, asparagine, creatine, choline phosphocholine, uracil, histidine and phenylalanine in the pancreas, with leucine, isoleucine, valine, alanine, glutamate, glutamine, glutathione, glycerophosphocholine, glycine, glucose and tyrosine commonly altered in the spleen and pancreas. A comparison of normal vs Pa04C_ SLC1A5 tumor bearing mice identified similar metabolic changes in the spleen and pancreas but these were reduced. Fumarate did not change in the spleen, and of the metabolic changes common to spleen and pancreas, glutamine did not change when tumor SLC1A5 was downregulated. Metabolite changes induced only in the pancreas were also similar to normal vs EV/WT with the exception of a change in glutamine with SLC1A5 downregulation and no change in lactate. Our data highlight the profound metabolic changes in spleen and pancreas metabolism that occur with growth of a cachexia-inducing pancreatic cancer xenograft, and the impact on these metabolic patterns as a result of downregulating the glutamine transporter in these cancer cells. The metabolic patterns identified in the spleen and pancreas may provide novel targets to reduce the morbidity from cachexia. Reference: 1. Son J et al, Nature. 2013;496(7443):101-5. Citation Format: Raj Kumar Sharma, Santosh Kumar Bharti, Balaji Krishnamachary, Yelena Mironchik, Paul Winnard Jr., Marie-France Penet, Zaver M. Bhujwalla. Metabolic changes in the spleen and pancreas induced by PDAC xenografts with or without glutamine transporter downregulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6353.
- Open Access
- 21 January 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1537
Ovarian Cancer Targeted Theranostics
Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30-40%. Most recurrent ovarian tumors are resistant to traditional therapies underscoring the need for new therapeutic options. Theranostic agents, that combine diagnostic and therapeutic capabilities, are being explored to better detect, diagnose and treat ovarian cancer. To minimize morbidity, improve survival rates, and eventually cure patients, new strategies are needed for early detection and for delivering specifically anticancer therapies to tumor sites. In this review we will discuss various molecular imaging modalities and targets that can be used for imaging, therapeutic and theranostic agent development for improved diagnosis and treatment of ovarian cancer.
- 21 January 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1537
Open AccessOvarian Cancer Targeted Theranostics
Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30-40%. Most recurrent ovarian tumors are resistant to traditional therapies underscoring the need for new therapeutic options. Theranostic agents, that combine diagnostic and therapeutic capabilities, are being explored to better detect, diagnose and treat ovarian cancer. To minimize morbidity, improve survival rates, and eventually cure patients, new strategies are needed for early detection and for delivering specifically anticancer therapies to tumor sites. In this review we will discuss various molecular imaging modalities and targets that can be used for imaging, therapeutic and theranostic agent development for improved diagnosis and treatment of ovarian cancer.
- 28 January 2019
- Published by Wiley in NMR in Biomedicine
- Vol. 32 (10) , e4053
MRI and MRS of intact perfused cancer cell metabolism, invasion, and stromal cell interactions
Because of the spatial and temporal heterogeneities of cancers, technologies to investigate cancer cells and the consequences of their interactions with abnormal physiological environments, such as hypoxia and acidic extracellular pH, with stromal cells, and with the extracellular matrix, under controlled conditions, are valuable to gain insights into the functioning of cancers. These insights can lead to an understanding of why cancers invade and metastasize, and identify effective treatment strategies. Here we have provided an overview of the applications of MRI/MRS/MRSI to investigate intact perfused cancer cells, their metabolism and invasion, and their interactions with stromal cells and the extracellular matrix.
- 28 January 2019
- Published by Wiley in NMR in Biomedicine
- Vol. 32 (10) , e4053
MRI and MRS of intact perfused cancer cell metabolism, invasion, and stromal cell interactions
Because of the spatial and temporal heterogeneities of cancers, technologies to investigate cancer cells and the consequences of their interactions with abnormal physiological environments, such as hypoxia and acidic extracellular pH, with stromal cells, and with the extracellular matrix, under controlled conditions, are valuable to gain insights into the functioning of cancers. These insights can lead to an understanding of why cancers invade and metastasize, and identify effective treatment strategies. Here we have provided an overview of the applications of MRI/MRS/MRSI to investigate intact perfused cancer cells, their metabolism and invasion, and their interactions with stromal cells and the extracellular matrix.
- Open Access
- 17 December 2018
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 8, 595
Ascites Volumes and the Ovarian Cancer Microenvironment
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy among women in developed countries. Epithelial ovarian cancer has a poor prognosis, due to the aggressive characteristics of the disease combined with the lack of effective therapies. Options for late-stage ovarian cancer are limited and invasive, especially once malignant ascites develops. Malignant ascites, a complication observed in terminal ovarian cancer, significantly contributes to poor quality of life and to mortality. Excess accumulation of fluid in the peritoneal cavity occurs due to a combination of impaired fluid drainage and increased net filtration, mostly due to increasing intraperitoneal vascular permeability. Here we applied non-invasive magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) of syngeneic mouse tumors in vivo, and high-resolution 1H MRS of mouse tumor extracts, to characterize the relationship between ascites volumes and the vasculature and metabolism of an experimental model of ovarian cancer. Differences were observed in the tumor vasculature and metabolism in tumors based on ascites volumes that provide new insights into the development of this condition.
- 17 December 2018
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 8, 595
Open AccessAscites Volumes and the Ovarian Cancer Microenvironment
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy among women in developed countries. Epithelial ovarian cancer has a poor prognosis, due to the aggressive characteristics of the disease combined with the lack of effective therapies. Options for late-stage ovarian cancer are limited and invasive, especially once malignant ascites develops. Malignant ascites, a complication observed in terminal ovarian cancer, significantly contributes to poor quality of life and to mortality. Excess accumulation of fluid in the peritoneal cavity occurs due to a combination of impaired fluid drainage and increased net filtration, mostly due to increasing intraperitoneal vascular permeability. Here we applied non-invasive magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) of syngeneic mouse tumors in vivo, and high-resolution 1H MRS of mouse tumor extracts, to characterize the relationship between ascites volumes and the vasculature and metabolism of an experimental model of ovarian cancer. Differences were observed in the tumor vasculature and metabolism in tumors based on ascites volumes that provide new insights into the development of this condition.
- 1 June 2018
- Published by Elsevier in Journal of Magnetic Resonance
- Vol. 291, 141-151
Theranostics and metabolotheranostics for precision medicine in oncology
- 1 June 2018
- Published by Elsevier in Journal of Magnetic Resonance
- Vol. 291, 141-151
Theranostics and metabolotheranostics for precision medicine in oncology
- 24 August 2017
- Published by Springer Nature in Metabolomics
- Vol. 13 (10) , 1-11
Metabolomic characterization of experimental ovarian cancer ascitic fluid
Introduction Malignant ascites (MA) is a major cause of morbidity that occurs in 37% of ovarian cancer patients. The accumulation of MA in the peritoneal cavity due to cancer results in debilitating symptoms and extremely poor quality of life. There is an urgent unmet need to expand the understanding of MA to design effective treatment strategies, and to improve MA diagnosis. Objective Our purpose here is to contribute to a better characterization of MA metabolic composition in ovarian cancer. Method We determined the metabolic composition of ascitic fluids resulting from orthotopic growth of two ovarian cancer cell lines, the mouse ID8- vascular endothelial growth factor (VEGF)-Defb29 cell line and the human OVCAR3 cell line using high-resolution 1H MRS. ID8-VEGF-Defb29 tumors induce large volumes of ascites, while OVCAR3 tumors induce ascites less frequently and at smaller volumes. To better understand the factors driving the metabolic composition of the fluid, we characterized the metabolism of these ovarian cancer cells in culture by analyzing cell lysates and conditioned culture media with 1H NMR. Results Distinct metabolite patterns were detected in ascitic fluid collected from OVCAR3 and ID8-VEGF-Defb29 tumor bearing mice that were not reflected in the corresponding cell culture or conditioned medium. Conclusion High-resolution 1H NMR metabolic markers of MA can be used to improve characterization and diagnosis of MA. Metabolic characterization of MA can provide new insights into how MA fluid supports cancer cell growth and resistance to treatment, and has the potential to identify metabolic targeting strategies to reduce or eliminate the formation of MA.
- 24 August 2017
- Published by Springer Nature in Metabolomics
- Vol. 13 (10) , 1-11
Metabolomic characterization of experimental ovarian cancer ascitic fluid
Introduction Malignant ascites (MA) is a major cause of morbidity that occurs in 37% of ovarian cancer patients. The accumulation of MA in the peritoneal cavity due to cancer results in debilitating symptoms and extremely poor quality of life. There is an urgent unmet need to expand the understanding of MA to design effective treatment strategies, and to improve MA diagnosis. Objective Our purpose here is to contribute to a better characterization of MA metabolic composition in ovarian cancer. Method We determined the metabolic composition of ascitic fluids resulting from orthotopic growth of two ovarian cancer cell lines, the mouse ID8- vascular endothelial growth factor (VEGF)-Defb29 cell line and the human OVCAR3 cell line using high-resolution 1H MRS. ID8-VEGF-Defb29 tumors induce large volumes of ascites, while OVCAR3 tumors induce ascites less frequently and at smaller volumes. To better understand the factors driving the metabolic composition of the fluid, we characterized the metabolism of these ovarian cancer cells in culture by analyzing cell lysates and conditioned culture media with 1H NMR. Results Distinct metabolite patterns were detected in ascitic fluid collected from OVCAR3 and ID8-VEGF-Defb29 tumor bearing mice that were not reflected in the corresponding cell culture or conditioned medium. Conclusion High-resolution 1H NMR metabolic markers of MA can be used to improve characterization and diagnosis of MA. Metabolic characterization of MA can provide new insights into how MA fluid supports cancer cell growth and resistance to treatment, and has the potential to identify metabolic targeting strategies to reduce or eliminate the formation of MA.
- Open Access
- 16 November 2016
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 6, 244
Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism
Epithelial ovarian cancer remains the leading cause of death from gynecologic malignancy among women in developed countries. New therapeutic strategies evaluated with relevant preclinical models are urgently needed to improve survival rates. Here we have assessed the effect of pantethine on tumor growth and metabolism using magnetic resonance imaging (MRI) and high-resolution proton magnetic resonance spectroscopy (MRS) in a model of ovarian cancer. To evaluate treatment strategies, it is important to use models that closely mimic tumor growth in humans. We therefore used an orthotopic model of ovarian cancer where a piece of tumor tissue, derived from an ovarian tumor xenograft, is engrafted directly onto the ovary of female mice, to maintain the tumor physiological environment. Treatment with pantethine, the precursor of vitamin B5 and active moiety of coenzyme A, was started when tumors were approximately 100 mm3, and consisted of a daily i.p. injection of 750 mg/kg in saline. Under these conditions, no side effects were observed. High-resolution 1H MRS was performed on treated and control tumor extracts. A dual-phase extraction method based on methanol/chloroform/water was used to obtain lipid and water-soluble fractions from the tumors. We also investigated effects on metastases and ascites formation. Pantethine treatment resulted in slower tumor progression, decreased levels of phosphocholine and phosphatidylcholine, and reduced metastases and ascites occurrence. In conclusion, pantethine represents a novel potential, well-tolerated, therapeutic tool in patients with ovarian cancer. Further in vivo preclinical studies are needed to confirm the beneficial role of pantethine and to better understand its mechanism of action.
- 16 November 2016
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 6, 244
Open AccessEffect of Pantethine on Ovarian Tumor Progression and Choline Metabolism
Epithelial ovarian cancer remains the leading cause of death from gynecologic malignancy among women in developed countries. New therapeutic strategies evaluated with relevant preclinical models are urgently needed to improve survival rates. Here we have assessed the effect of pantethine on tumor growth and metabolism using magnetic resonance imaging (MRI) and high-resolution proton magnetic resonance spectroscopy (MRS) in a model of ovarian cancer. To evaluate treatment strategies, it is important to use models that closely mimic tumor growth in humans. We therefore used an orthotopic model of ovarian cancer where a piece of tumor tissue, derived from an ovarian tumor xenograft, is engrafted directly onto the ovary of female mice, to maintain the tumor physiological environment. Treatment with pantethine, the precursor of vitamin B5 and active moiety of coenzyme A, was started when tumors were approximately 100 mm3, and consisted of a daily i.p. injection of 750 mg/kg in saline. Under these conditions, no side effects were observed. High-resolution 1H MRS was performed on treated and control tumor extracts. A dual-phase extraction method based on methanol/chloroform/water was used to obtain lipid and water-soluble fractions from the tumors. We also investigated effects on metastases and ascites formation. Pantethine treatment resulted in slower tumor progression, decreased levels of phosphocholine and phosphatidylcholine, and reduced metastases and ascites occurrence. In conclusion, pantethine represents a novel potential, well-tolerated, therapeutic tool in patients with ovarian cancer. Further in vivo preclinical studies are needed to confirm the beneficial role of pantethine and to better understand its mechanism of action.